The estimated Net Worth of Ruedi E Waeger is at least $4.4 Milhão dollars as of 3 May 2010. Ruedi Waeger owns over 3,000 units of Alexion Pharmaceuticals stock worth over $4,403,806 and over the last 20 years Ruedi sold ALXN stock worth over $0.
Ruedi has made over 3 trades of the Alexion Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Ruedi bought 3,000 units of ALXN stock worth $165,300 on 3 May 2010.
The largest trade Ruedi's ever made was exercising 19,500 units of Alexion Pharmaceuticals stock on 31 July 2008 worth over $394,485. On average, Ruedi trades about 2,036 units every 49 days since 2005. As of 3 May 2010 Ruedi still owns at least 24,054 units of Alexion Pharmaceuticals stock.
You can see the complete history of Ruedi Waeger stock trades at the bottom of the page.
Ruedi's mailing address filed with the SEC is C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE, CT, 06410.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell, ePaul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: